- Home
- SES vs IMTX Comparison
SES vs IMTX Comparison
Compare SES & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SES
- IMTX
- Stock Information
- Founded
- SES 2012
- IMTX N/A
- Country
- SES United States
- IMTX Germany
- Employees
- SES N/A
- IMTX N/A
- Industry
- SES Auto Parts:O.E.M.
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SES Consumer Discretionary
- IMTX Health Care
- Exchange
- SES Nasdaq
- IMTX Nasdaq
- Market Cap
- SES 1.0B
- IMTX 1.1B
- IPO Year
- SES N/A
- IMTX N/A
- Fundamental
- Price
- SES $1.99
- IMTX $10.25
- Analyst Decision
- SES Buy
- IMTX Strong Buy
- Analyst Count
- SES 1
- IMTX 4
- Target Price
- SES $4.00
- IMTX $13.67
- AVG Volume (30 Days)
- SES 12.6M
- IMTX 654.5K
- Earning Date
- SES 11-05-2025
- IMTX 11-14-2025
- Dividend Yield
- SES N/A
- IMTX N/A
- EPS Growth
- SES N/A
- IMTX N/A
- EPS
- SES N/A
- IMTX N/A
- Revenue
- SES $18,478,000.00
- IMTX $152,823,253.00
- Revenue This Year
- SES $883.92
- IMTX N/A
- Revenue Next Year
- SES $159.98
- IMTX $13.52
- P/E Ratio
- SES N/A
- IMTX N/A
- Revenue Growth
- SES N/A
- IMTX 83.61
- 52 Week Low
- SES $0.20
- IMTX $3.30
- 52 Week High
- SES $3.73
- IMTX $11.25
- Technical
- Relative Strength Index (RSI)
- SES 42.51
- IMTX 56.67
- Support Level
- SES $2.08
- IMTX $8.92
- Resistance Level
- SES $2.61
- IMTX $10.86
- Average True Range (ATR)
- SES 0.27
- IMTX 0.63
- MACD
- SES -0.06
- IMTX -0.05
- Stochastic Oscillator
- SES 24.39
- IMTX 71.66
About SES SES AI Corporation
SES AI Corp is a developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (Li-Metal) and Lithium-ion (Li-ion) rechargeable battery technologies for electric vehicles (EVs), Urban Air Mobility (UAM), drones, robotics, Battery Energy Storage Systems (BESS) and other applications. It includes Software and Hardware products that are EV, UAM, Drone, Molecular Universe, and Avatar.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.